MiNK Therapeutics (NASDAQ:INKT – Get Free Report) and Orchard Therapeutics (NASDAQ:ORTX – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, analyst recommendations and valuation.
Profitability
This table compares MiNK Therapeutics and Orchard Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| MiNK Therapeutics | N/A | -665.42% | -137.78% |
| Orchard Therapeutics | -399.58% | -78.74% | -37.76% |
Insider and Institutional Ownership
1.4% of MiNK Therapeutics shares are owned by institutional investors. Comparatively, 29.9% of Orchard Therapeutics shares are owned by institutional investors. 17.8% of MiNK Therapeutics shares are owned by company insiders. Comparatively, 2.9% of Orchard Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| MiNK Therapeutics | 0 | 0 | 3 | 0 | 3.00 |
| Orchard Therapeutics | 0 | 0 | 2 | 0 | 3.00 |
MiNK Therapeutics currently has a consensus price target of $6.50, suggesting a potential upside of 385.07%. Orchard Therapeutics has a consensus price target of $24.50, suggesting a potential upside of 308.33%. Given MiNK Therapeutics’ higher possible upside, research analysts plainly believe MiNK Therapeutics is more favorable than Orchard Therapeutics.
Earnings & Valuation
This table compares MiNK Therapeutics and Orchard Therapeutics’ revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| MiNK Therapeutics | N/A | N/A | -$27.99 million | ($0.77) | -1.74 |
| Orchard Therapeutics | $22.66 million | 6.02 | -$150.66 million | ($4.49) | -1.34 |
MiNK Therapeutics has higher earnings, but lower revenue than Orchard Therapeutics. MiNK Therapeutics is trading at a lower price-to-earnings ratio than Orchard Therapeutics, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
MiNK Therapeutics has a beta of -0.26, meaning that its share price is 126% less volatile than the S&P 500. Comparatively, Orchard Therapeutics has a beta of 0.92, meaning that its share price is 8% less volatile than the S&P 500.
About MiNK Therapeutics
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. It's product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.
About Orchard Therapeutics
Orchard Therapeutics plc, a gene therapy company, research, develops, and commercialize hematopoietic stem cell and gene therapies in the United Kingdom, Italy, France, and Germany. It offers OTL-200, an ex vivo autologous hematopoietic stem cell gene therapy for the treatment of patients with metachromatic leukodystrophy under the Libmeldy brand; and Strimvelis, a gammaretroviral vector-based gene therapy for the treatment of adenosine deaminase deficiency. The company's program for neurodegenerative disorders comprises clinical proof of concept-stage program, which includes OTL-203 for the treatment of mucopolysaccharidosis type I and OTL-201 for mucopolysaccharidosis type IIIA, or MPS-IIIA; and pre-clinical program, OTL-204 for the treatment of frontotemporal dementia with progranulin mutations. In addition, it develops program for immunological disorders consist of pre-clinical programs, which includes OTL-104 for Crohn's disease with mutations in the nucleotide-binding oligomerization domain-containing protein 2; and OTL-105 for the treatment of hereditary angioedema. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom.
Receive News & Ratings for MiNK Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiNK Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
